Sutro Biopharma, Inc.: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 14, 2018 and accepted by EDGAR at Nov 14, 2018, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2018-07-01 to 2018-09-30 | $12.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2018-01-01 to 2018-09-30 | $39.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$10.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | −$33.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-07-01 to 2018-09-30 | $415.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2018-01-01 to 2018-09-30 | $1.2m | us-gaap:InterestExpense |
| Net income | 3 months2018-07-01 to 2018-09-30 | −$10.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | −$33.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | −$21.26 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | −$71.06 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | $18.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2018-01-01 to 2018-09-30 | $759.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-09-30 | $41.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $127.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $145.0m | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $36.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $99.2m | us-gaap:Liabilities |
| Long-term debt | At period end2018-09-30 | $11.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2018-09-30 | $3.2m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2018-09-30 | −$141.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-18-029555. Last ingested by Listed: Nov 13, 2026, 16:35 ET. Listed shows no prices and gives no investment advice.